Investors sold shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) on strength during trading on Friday. $41.84 million flowed into the stock on the tick-up and $85.27 million flowed out of the stock on the tick-down, for a money net flow of $43.43 million out of the stock. Of all stocks tracked, Alexion Pharmaceuticals had the 0th highest net out-flow for the day. Alexion Pharmaceuticals traded up $1.08 for the day and closed at $124.42

Several research analysts recently commented on ALXN shares. Barclays PLC increased their price objective on Alexion Pharmaceuticals from $175.00 to $180.00 and gave the company an “equal weight” rating in a research note on Monday, May 9th. Leerink Swann reissued an “outperform” rating on shares of Alexion Pharmaceuticals in a research note on Sunday, April 10th. Vetr downgraded Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $161.67 price objective for the company. in a research note on Monday, April 4th. Citigroup Inc. raised Alexion Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $154.00 price objective for the company in a research note on Monday, June 27th. Finally, BMO Capital Markets started coverage on Alexion Pharmaceuticals in a research note on Wednesday, April 6th. They issued a “market perform” rating and a $165.00 price objective for the company. Eight research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $193.07.

The firm has a market capitalization of $27.87 billion and a PE ratio of 188.23. The firm has a 50 day moving average of $132.82 and a 200-day moving average of $145.76.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Thursday, April 28th. The biopharmaceutical company reported $1.11 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.13 by $0.02. The company earned $701 million during the quarter, compared to analysts’ expectations of $710.98 million. The company’s revenue was up 16.8% on a year-over-year basis. During the same period in the prior year, the firm earned $1.28 EPS. On average, equities analysts forecast that Alexion Pharmaceuticals Inc. will post $5.05 EPS for the current year.

In related news, EVP Martin Mackay sold 4,097 shares of the company’s stock in a transaction on Monday, May 16th. The stock was sold at an average price of $139.20, for a total value of $570,302.40. Following the completion of the transaction, the executive vice president now directly owns 42,706 shares in the company, valued at $5,944,675.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP John B. Moriarty sold 918 shares of the company’s stock in a transaction on Monday, June 13th. The shares were sold at an average price of $135.72, for a total value of $124,590.96. Following the completion of the transaction, the executive vice president now owns 51,360 shares of the company’s stock, valued at $6,970,579.20. The disclosure for this sale can be found here.

A number of institutional investors have added to or reduced their stakes in ALXN. Jennison Associates LLC raised its position in Alexion Pharmaceuticals by 7.0% in the fourth quarter. Jennison Associates LLC now owns 7,346,024 shares of the biopharmaceutical company’s stock valued at $1,401,254,000 after buying an additional 481,031 shares during the last quarter. Brown Advisory Inc. raised its stake in shares of Alexion Pharmaceuticals by 17.7% in the fourth quarter. Brown Advisory Inc. now owns 2,233,531 shares of the biopharmaceutical company’s stock valued at $426,046,000 after buying an additional 335,663 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Alexion Pharmaceuticals by 2.0% in the fourth quarter. Vanguard Group Inc. now owns 12,973,958 shares of the biopharmaceutical company’s stock valued at $2,474,783,000 after buying an additional 252,272 shares in the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of Alexion Pharmaceuticals by 563.8% in the fourth quarter. BNP Paribas Arbitrage SA now owns 113,751 shares of the biopharmaceutical company’s stock valued at $21,698,000 after buying an additional 96,615 shares in the last quarter. Finally, State of Wisconsin Investment Board raised its stake in shares of Alexion Pharmaceuticals by 46.0% in the fourth quarter. State of Wisconsin Investment Board now owns 279,024 shares of the biopharmaceutical company’s stock valued at $53,224,000 after buying an additional 87,900 shares in the last quarter.

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.